Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters









Database
Language
Publication year range
1.
Statins: in the beginning.
Lyons, K S; Harbinson, M.
J R Coll Physicians Edinb ; 39(4): 362-4, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20509462

ABSTRACT

Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role ofAkira Endo.


Subject(s)
Anticholesteremic Agents/history , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , History, 20th Century , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Japan , Lovastatin/analogs & derivatives , Lovastatin/history
2.
JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Luckman, Steven P; Hughes, David E; Coxon, Fraser P; Russell, Graham G; Rogers, Michael J.
J Bone Miner Res ; 20(7): 1265-74, 2005 Jul.
Article in English | MEDLINE | ID: mdl-16050006

Subject(s)
Bone Resorption/history , Diphosphonates/history , Mevalonic Acid/history , ras Proteins/history , Animals , Bone Resorption/metabolism , Cells, Cultured , Diphosphonates/pharmacology , GTP-Binding Proteins/history , GTP-Binding Proteins/metabolism , History, 20th Century , Lovastatin/analogs & derivatives , Lovastatin/history , Lovastatin/pharmacology , Mevalonic Acid/metabolism , Mice , Osteoclasts/drug effects , Osteoclasts/metabolism , Protein Prenylation/drug effects , ras Proteins/metabolism
3.
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. 1976.
Endo, Akira; Kuroda, Masao; Tanzawa, Kazuhiko.
Atheroscler Suppl ; 5(3): 39-42, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15531273

Subject(s)
Anticholesteremic Agents/history , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Lovastatin/analogs & derivatives , Lovastatin/history , Naphthols/history , Animals , Anticholesteremic Agents/pharmacology , History, 20th Century , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Lovastatin/pharmacology , Naphthols/pharmacology , Rats
4.
Therapeutic effects of ml-236B in primary hypercholesterolemia. 1980.
Yammoto, Akira; Sudo, Hiroshi; Endo, Akira.
Atheroscler Suppl ; 5(3): 43-50, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15531274

Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Hypercholesterolemia/history , Lovastatin/analogs & derivatives , Lovastatin/history , History, 20th Century , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/drug therapy , Lovastatin/therapeutic use
5.
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Mabuchi, Hiroshi; Haba, Toshihiro; Tatami, Ryzo; Miyamoto, Susumu; Sakai, Yasuyuki; Wakasugi, Takanobu; Watanabe, Akira; Koizumi, Junji; Takeda, Ryoyu.
Atheroscler Suppl ; 5(3): 51-5, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15531275

Subject(s)
Anticholesteremic Agents/history , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/history , Lipoproteins/blood , Lovastatin/analogs & derivatives , Lovastatin/history , Ubiquinone/analogs & derivatives , Ubiquinone/blood , Anticholesteremic Agents/therapeutic use , Coenzymes , History, 20th Century , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/drug therapy , Lovastatin/therapeutic use
6.
Lowering plasma cholesterol by raising ldl receptors. 1981.
Brown, Michael S; Goldstein, Joseph L.
Atheroscler Suppl ; 5(3): 57-9, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15531276

Subject(s)
Anticholesteremic Agents/history , Cholesterol/history , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Lovastatin/analogs & derivatives , Lovastatin/history , Receptors, LDL/history , Animals , Anticholesteremic Agents/pharmacology , Cholesterol/blood , History, 20th Century , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/drug therapy , Hyperlipoproteinemia Type II/history , Lovastatin/pharmacology , Receptors, LDL/blood
7.
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
Bilheimer, David W; Grundy, Scott M; Brown, Michael S; Goldstein, Joseph L.
Atheroscler Suppl ; 5(3): 61-5, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15531277

Subject(s)
Colestipol/history , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Hyperlipoproteinemia Type II/history , Lipoproteins, LDL/history , Lovastatin/history , Colestipol/therapeutic use , History, 20th Century , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/drug therapy , Lipoproteins, LDL/blood , Lovastatin/therapeutic use
8.
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
Patchett, Arthur A.
J Med Chem ; 45(26): 5609-16, 2002 Dec 19.
Article in English | MEDLINE | ID: mdl-12477342

Subject(s)
Awards and Prizes , Biological Products/history , Chemistry, Organic , Drug Design , Angiotensin-Converting Enzyme Inhibitors/chemical synthesis , Angiotensin-Converting Enzyme Inhibitors/history , Antihypertensive Agents/chemical synthesis , Antihypertensive Agents/history , Benzodiazepinones/chemical synthesis , Benzodiazepinones/history , Biological Products/chemistry , History, 20th Century , History, 21st Century , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/history , Lovastatin/chemical synthesis , Lovastatin/history , United States
9.
The discovery and development of HMG-CoA reductase inhibitors.
Endo, A.
J Lipid Res ; 33(11): 1569-82, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1464741

Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors , Lovastatin/analogs & derivatives , Animals , Anticholesteremic Agents/history , Anticholesteremic Agents/pharmacology , History, 20th Century , Humans , Hypercholesterolemia/drug therapy , Lovastatin/history , Lovastatin/pharmacology
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL